FAIRFIELD, N.J., Feb. 15 /PRNewswire-FirstCall/ -- Astralis Ltd. (BULLETIN BOARD: ASTR) today announced the appointment of Mr. James Sharpe as Chief Executive Officer.
"Mr. Sharpe has significant experience in managing drug development companies. His expertise in the areas of finance, emerging biotechnology, and healthcare will facilitate Astralis' financial and clinical goals," noted Dr. Jose O'Daly, Chairman and principal founder of Astralis.
Prior to joining Astralis, from 1999 to 2005, Mr. Sharpe served as President and founder of Ankyr Consulting, L.L.C, an independent consulting company focused on strategy, business development, finance, mergers, acquisitions and operations for healthcare and biotechnology companies. From 1991 to 2005, he founded or served as President or executive management of several biotechnology companies involved in drug discovery, drug delivery, vaccines and gene therapy.
Mr. Sharpe stated, "Astralis has a unique technology platform which stems from a fascinating discovery in the area of immune system disorders and skin diseases. Our continued goal at Astralis is to bring our first product candidate, Psoraxine(R) for the treatment of Psoriasis, to market, as well as to continue our research and product development efforts in our other target areas."
Mr. Sharpe has a B.S. in Chemistry from Union College, and a MBA in Marketing and Finance from the University of Rochester. He was a founding member of the Pennsylvania Biotechnology Association, where he served as President for two years (1990-1992) and was a member of the Board of Directors for eight years (1989-1997). He also served for three years (1993 to 1996) as a member of the Board of Governors of the Emerging Company Section of the Biotechnology Industry Association (BIO).
Notes to the Editor
Astralis Ltd., a biotechnology company based in New Jersey, focuses on the research and development of novel treatments for immune system disorders and skin diseases. Psoraxine(R), administered by intramuscular injection, is a protein-based therapy that is believed to stimulate cells from the patient's immune system to reverse the inflammatory process responsible for psoriasis symptoms. Psoraxine(R) is currently being tested in U.S. Phase II clinical trials. For more information, visit Astralis' web site at http://www.astralisltd.com/.
75 Passaic Ave
Fairfield, New Jersey, 07004
Fax: 1 (973) 227- 7169
Phone: 1 (973) 227- 7168
This news release contains forward-looking statements based on information available to Astralis as of the date hereof. Astralis' actual results could differ materially from the results stated or implied by such forward-looking statements due to a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, general economic and business conditions, changes in governmental laws and regulations relating to the development and commercialization of pharmaceutical products, and competition in our industry. There can be no assurance that our product development efforts will succeed, that Psoraxine will receive required regulatory clearance or that, even if such regulatory clearance were received, that Psoraxine will ultimately achieve commercial success. Astralis disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.